PubRank

Molecular therapy. Nucleic acids (Mol Ther Nucleic Acids)

Journal PubWeight™ 339.63‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Mir-34: a new weapon against cancer? 2014 1.81
2 Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. 2014 1.58
3 Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. 2012 1.53
4 Oligonucleotide aptamers: new tools for targeted cancer therapy. 2014 1.49
5 The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. 2014 1.46
6 CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. 2013 1.45
7 Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. 2012 1.41
8 BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. 2013 1.40
9 Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. 2013 1.38
10 Targeting Hepatitis B Virus With CRISPR/Cas9. 2014 1.33
11 Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. 2014 1.32
12 COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. 2014 1.27
13 An RNA alternative to human transferrin: a new tool for targeting human cells. 2012 1.25
14 Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. 2012 1.24
15 Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. 2015 1.23
16 New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization. 2014 1.21
17 Nonviral direct conversion of primary mouse embryonic fibroblasts to neuronal cells. 2012 1.20
18 miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. 2012 1.18
19 TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. 2013 1.16
20 Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. 2012 1.16
21 Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. 2013 1.14
22 What Can We Learn From Clinical Trials of Exon Skipping for DMD? 2014 1.13
23 Targeting DNA With Fingers and TALENs. 2012 1.12
24 siRNA Versus miRNA as Therapeutics for Gene Silencing. 2015 1.12
25 FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections. 2015 1.11
26 Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. 2013 1.10
27 Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. 2014 1.09
28 The MicroRNA Biology of the Mammalian Nucleus. 2014 1.05
29 Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. 2013 1.05
30 Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. 2012 1.05
31 In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. 2014 1.03
32 Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer. 2013 1.03
33 Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. 2015 1.02
34 AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation. 2012 1.01
35 The Business of RNAi Therapeutics in 2012. 2012 1.01
36 MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. 2015 0.99
37 A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. 2013 0.99
38 Pol III Promoters to Express Small RNAs: Delineation of Transcription Initiation. 2014 0.99
39 CD28 aptamers as powerful immune response modulators. 2013 0.98
40 In vivo SELEX for Identification of Brain-penetrating Aptamers. 2013 0.98
41 Designing Ago2-specific siRNA/shRNA to Avoid Competition with Endogenous miRNAs. 2014 0.97
42 Design and Development of Artificial Zinc Finger Transcription Factors and Zinc Finger Nucleases to the hTERT Locus. 2013 0.97
43 A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. 2012 0.97
44 CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice. 2014 0.96
45 Triple bioluminescence imaging for in vivo monitoring of cellular processes. 2013 0.96
46 Focal Delivery of AAV2/1-transgenes Into the Rat Brain by Localized Ultrasound-induced BBB Opening. 2013 0.95
47 Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. 2012 0.95
48 Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages. 2013 0.94
49 Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. 2012 0.94
50 Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. 2013 0.94
Next 50